Tirzepatide vs Retatrutide
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist used in metabolic optimization. Retatrutide is an investigational triple-agonist (GIP/GLP-1/glucagon) with promising Phase 2 data but is not yet FDA-approved for clinical use.
Tirzepatide is the modern dual-agonist standard for metabolic optimization, available in the oMeds weight-loss pathway.
Retatrutide is investigational and not clinically available; candidates interested in triple-agonist therapy are routed to trial enrollment via external referral.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
When will retatrutide be available?
Pending Phase 3 readout and FDA review; not on a current clinical timeline.
Is tirzepatide enough for most candidates?
For most metabolic optimization candidates, tirzepatide is provider-reviewed as sufficient. Candidacy is biomarker- and goal-driven.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment